The effects of antipsychotic switching on diabetes in chronic schizophrenia

Diabetic Medicine

Volumn 31, Issue 3, 2014, Pages

  Arnoldy, R ^a   Curtis, J ^b,c   Samaras, K ^a,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b South Eastern Sydney Local Health District   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CLOZAPINE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84894056086     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12359     Document Type: Article

References (16)

1. Thornicroft G. Premature death among people with mental illness. Br Med J 2013; 346: f2969.
2. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245.
3. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131.
5. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004; 47: S67-71.
6. Cohen D, Stolk RP, Grobbee DE. Gispen-de Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006; 29: 786-791.
7. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004; 47: S64-66.
8. Hert M, Correll C, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
9. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233.
10. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-126.
11. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
12. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005; 165: 2631-2638.
13. Lawrence D, Kisely S. Inequalities in health care provision for people with severe mental illness. J Psychopharmacol 2010; 24: 61-68.
14. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013; 70: 722-727.
15. Samaras K, Correll CU, Mitchell AJ, De Hert M. Diabetes risk potentially underestimated in youth and children receiving antipsychotics. JAMA Psychiatry 2013. (in press).
16. Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry 2012; 6: 347-353.